Current Status
Not Enrolled
Get Started

Global ASCVD Trends and Emerging Strategies

Program Director

Peter Libby, MD

Program Director

Raul D Santos, MD, MSc, PhD

The IAS has developed the worldwide effort aimed at health care professionals to comprehensively address the matter of LDL-C attributable risk in the prevention of Major Adverse Cardiology Events (MACE) and mortality  This will be accomplished through a series of nine (9) videos presented by some of the most recognizable and prominent leaders in cardiology and lipid medicine from across the globe. 

Importantly, the videos will emphasize the translation of current guidelines and evidence into practice approaches that heighten both clinical and patient success.  Every video, based on real-world issues and evidence, will focus on implementing practical physician and patient strategies. 

The videos are presented in
English, but we have added subtitles in four (4) additional languages:  Arabic, Spanish, Portuguese and Chinese.  

            Click on the button of your preferred language below.

Pre-Activty Information

Vídeo 3: Farmacoterapias para obesidade e prevenção de DCV

Video 3: Pharmacotherapies for Obesity and CVD Prevention

Vídeo 2: Obesidade e Lesão em Órgãos-Alvo

Video 2: Obesity and Target Organ Damage

Vídeo 1: Epidemiologia da Obesidade e Doença Cardiovascular

Video 1: Epidemiology and Pathophysiology of Obesity and CVD

SESSÃO DE ABERTURA: Manejo da Obesidade – A Perspectiva do Paciente e do Provedor

Video 1: Epidemiology and pathophysiology of obesity and CVD

Part 4: Round table with the experts: Where do we stand in our battle against the ravages of diabetes?

Part 3 – Session B: Therapeutic options for prevention of cardiovascular disease

Part 3 – Session A: A Hierarchy of Treatment Approaches based on Severity for the T2DM Patient with ASCVD

Part 2: Combating Atherosclerosis: Assessing CV Patient Risk for the T2DM Patient

Part 1: The History in the Battle of Insulin and Glucagon

Parte 4, Mesa redonda com os especialistas – Onde estamos em nossa batalha contra os danos do diabetes?

Parte 3, Sessão B – Opções terapêuticas para prevenção de doenças cardiovasculares

« » page 1 / 14